B-cell malignancies can be treated with licensed antibody-based TRT radiopharmaceuticals targeting upregulated receptors including CD20, whereas neuroendocrine and prostate cancers can be treated with licensed small-molecule TRT radiopharmaceuticals targeting the somatostatin receptor and PSMA, respectively. This evidence concerns the gene FOLH1 and prostate carcinoma.